Weekly Cumulative Estimated Number of Updated 2023-24 COVID-19 Vaccinations Administered in Pharmacies and Physical Medical Offices, Adults 18 Years and Older, United States

• Estimated number of updated COVID-19 vaccinations among adults 18 years and older is assessed through IQVIA (https://www.iqvia.com/) as a source of information on vaccinations administered in retail pharmacies (include chain, mass merchandise, food stores, and independent pharmacies) and physician medical offices.

• Starting in September 2023, the CDC recommended the updated 2023-2024 COVID-19 vaccine for adults ages 18 years and older.

The Real World Evidence (RWE) solutions market is experiencing robust growth, projected to reach $1008.6 million in 2025 and maintain a Compound Annual Growth Rate (CAGR) of 12% from 2025 to 2033. This expansion is fueled by several key drivers. The increasing adoption of digital health technologies, including electronic health records (EHRs) and wearable sensors, provides a rich source of data for RWE generation. Furthermore, regulatory bodies are increasingly embracing RWE to support drug approvals and post-market surveillance, accelerating market penetration. The rising prevalence of chronic diseases and the need for more cost-effective healthcare solutions further underpin the demand for RWE. Key players like IQVIA, IBM, and Parexel are strategically investing in advanced analytics and data integration platforms to capitalize on this market opportunity. The market is segmented by solution type (e.g., data acquisition, analytics, consulting), application (e.g., drug development, regulatory submissions, post-market surveillance), and end-user (e.g., pharmaceutical companies, healthcare providers, regulatory agencies). Competition is intense, with established players facing challenges from emerging technology providers focusing on innovative data processing and AI-driven insights. The projected market size in 2033, extrapolated from the provided CAGR, is approximately $3,246 million. However, this estimate is subject to changes based on unforeseen market disruptions or technological breakthroughs. Sustained growth hinges on factors such as the continued development of robust data privacy regulations, the ability to integrate diverse data sources effectively, and the broader acceptance of RWE by healthcare stakeholders. Addressing data interoperability challenges and ensuring data security remain crucial for long-term market expansion. Future growth will likely see increased investment in artificial intelligence (AI) and machine learning (ML) to enhance the analytical capabilities of RWE platforms, allowing for more precise insights and predictive modeling.

This uses the data within PPM+, the EHR for the Leeds Cancer Centre and Leeds Teaching Hospitals. It includes all patients diagnosed with cancer since 1990, all chemotherapy since 1993, all radiotherapy since 1994. It integrates all sources of EHR data.

This dataset tracks the updates made on the dataset "Weekly Cumulative Estimated Number of Updated 2023-24 COVID-19 Vaccinations Administered in Pharmacies and Physician Medical Offices, Adults 18 years and older, United States, Data Source(s): IQVIA Pharmacy and Physician Medical Office Claims" as a repository for previous versions of the data and metadata.

Weekly Cumulative Estimated Number of Influenza Vaccinations Administered in Pharmacies and Physician Medical Offices, Adults 18 years and older, United States

• Since 2019, CDC has been exploring use of data obtained from (https://www.iqvia.com/) as a source of information on vaccinations administered in retail pharmacies (include chain, mass merchandise, food stores, and independent pharmacies) and physician medical offices. These data are being presented publicly for the first time this season; further evaluations of these data are underway.

• The pharmacy data include flu vaccinations that were billed for (i.e. claims) or paid by cash. Medical office data are claims based.

• The sampled pharmacies and physician medical offices and the captured volume of transactions represent approximately 92% and 82% of influenza vaccines administered nationally, respectively.

• Vaccinations administered in other settings such as workplaces and community settings are not included in these data.

• Weekly Number of Influenza Vaccinations Administered, in Pharmacies and Physician Medical Offices, Adults 18 years and older, United States, Data Source(s): IQVIA Pharmacy and Physician Medical Office Claims.

The global pharmacovigilance solutions market is experiencing robust growth, driven by increasing drug approvals, stringent regulatory requirements, and a rising incidence of adverse drug reactions (ADRs). The market, estimated at $10 billion in 2025, is projected to expand at a compound annual growth rate (CAGR) of 7% from 2025 to 2033, reaching approximately $16 billion by 2033. This growth is fueled by several key factors. Firstly, the increasing complexity of drug development necessitates advanced pharmacovigilance solutions to effectively monitor and manage safety risks. Secondly, regulatory bodies worldwide are enforcing stricter regulations, mandating comprehensive pharmacovigilance systems. Thirdly, the rising adoption of electronic health records (EHRs) and digital technologies provides valuable data sources for signal detection and analysis. Finally, the expansion of clinical trials in emerging markets contributes to the growth of the market. The market is segmented by application (preclinical, clinical phase, post-launch) and type (writing and submitting documents and reports; security database system services and data management; signal detection and evaluation; training and consulting; other). The post-launch segment holds the largest market share owing to the continuous monitoring required after drug approval. Within the services segment, data management and signal detection are gaining traction due to the massive data generated during drug development and post-market surveillance. North America currently dominates the market, followed by Europe and Asia Pacific. However, the Asia Pacific region is projected to witness the highest growth rate during the forecast period, driven by increasing healthcare expenditure and growing pharmaceutical industry. Key players are strategically investing in advanced technologies such as AI and machine learning to enhance data analysis and signal detection capabilities. This competitive landscape fosters innovation and drives market expansion.

The global pharmacovigilance (PV) outsourcing market is experiencing robust growth, driven by the increasing complexity of drug development and regulatory requirements, coupled with the rising volume of adverse event reports. The market's expansion is fueled by pharmaceutical and biotechnology companies' increasing reliance on external experts to manage their PV obligations efficiently and cost-effectively. This outsourcing trend allows companies to focus on core competencies while leveraging the specialized knowledge and technological capabilities of dedicated PV service providers. Key drivers include the rising adoption of advanced technologies such as artificial intelligence and machine learning for data analysis and signal detection, as well as the growing demand for real-world evidence generation to support post-market drug surveillance. The market is segmented by service type (e.g., signal detection, risk management, regulatory reporting), therapeutic area, and geography. Competition is intense, with a mix of large multinational corporations and smaller specialized firms vying for market share. While challenges exist, such as data privacy concerns and the need for standardized processes across global regions, the long-term outlook for the PV outsourcing market remains positive, indicating sustained growth throughout the forecast period. The market's growth trajectory is significantly influenced by regulatory changes and technological advancements. Stringent regulatory frameworks governing drug safety and post-market surveillance necessitate robust PV systems, pushing companies to outsource to meet compliance demands. Furthermore, advancements in data analytics and AI are improving the efficiency and effectiveness of PV activities, allowing for faster identification of safety signals and improved risk management. The increasing volume of data generated through electronic health records and other sources necessitates sophisticated analytics capabilities, which specialized outsourcing providers are well-positioned to offer. The geographical distribution of the market reflects the concentration of pharmaceutical industries and regulatory bodies, with North America and Europe currently holding significant market shares. However, emerging markets in Asia-Pacific and Latin America are witnessing rapid growth, driven by expanding healthcare infrastructure and rising drug consumption. This expansion presents significant opportunities for PV outsourcing providers to expand their global reach and cater to an increasing number of clients.

Market researchers investigate clients' target markets' behaviour, values and opinions, providing insights that allow them to tailor their products, services and marketing. Researchers rely on hefty European research and development expenditure to fuel demand for market research. The surge in digitalisation has opened new doors for market research providers while intensifying competition. Artificial intelligence is increasingly important in analysing, identifying and generating research insights from social media posts using a flood of data. Meanwhile, digital surveys have allowed research companies to expand their outreach, save resources and costs and often attain more accurate and comprehensive insights for clients. Over the five years through 2025, industry revenue is expected to contract at a compound annual rate of 1.1% to reach €25.2 billion. The high inflationary environment in recent years has taken a toll on market research budgets. A sharp contraction in business sentiment squeezed corporate profit in 2022, discouraging companies from investing in research and development activities and negatively affecting professional research providers. A greater availability of data and alternative research methods means that researchers are competing more and more with in-house research departments. In 2025, industry revenue is expected to drop by 0.3% as consumers are finding their research needs met by AI tools such as ChatGPT, however, this trend is expected to be short-lived as research companies will strive to prove their value to clients. Over the five years through 2030, industry revenue is forecast to swell at a compound annual rate of 3.7% to reach €30.3 billion. Over the coming years, market research companies will face higher external competition from technology specialists leveraging insights internally, constraining revenue growth. Nonetheless, researchers will benefit from expanding online advertising activity. Those incorporating advanced data analytics systems and digital market research technology will remain competitive and benefit from greater digitalisation. Smart mobile surveys will also become an invaluable tool for consumer research companies.